Genetics and heart failure: A concise guide for the clinician

Current Cardiology Reviews

Volumn 11, Issue 1, 2015, Pages 10-17

  Skrzynia, Cécile ^a   Berg, Jonathan S ^a   Willis, Monte S ^a   Jensen, Brian C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Dilated; Genetic counseling; Genetic testing; Genetics; Heart failure; Medical; Pharmacogenetics

Indexed keywords

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CARDIOLOGIST; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETICS; HEART FAILURE; HEREDITY; HERITABILITY; HUMAN; INHERITANCE; PHARMACOGENETICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE; X CHROMOSOMAL INHERITANCE; CHILD; MITOCHONDRION; RISK FACTOR; X CHROMOSOME;

CARDIOMYOPATHY, DILATED; CHILD; CHROMOSOMES, HUMAN, X; GENETIC TESTING; HEART FAILURE; HUMANS; MITOCHONDRIA; RISK FACTORS;

EID: 84919683262     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403x09666131117170446     Document Type: Article

References (49)

1. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006; 355: 138-47.
2. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Annu Rev Med 2012; 63: 35-61.
3. Conrad DF, Jakobsson M, Coop G, et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 2006; 38: 1251-60.
4. Golbus JR, Puckelwartz MJ, Fahrenbach JP, et al. Populationbased variation in cardiomyopathy genes. Circ Cardiovasc Genet 2012; 5: 391-9.
5. Norton N, Robertson PD, Rieder MJ, et al. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet 2012; 5: 167-74.
6. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290(5806): 457-65.
7. Musunuru K, Kathiresan S. HapMap and mapping genes for cardiovascular disease. Circ Cardiovasc Genet 2008; 1: 66-71.
8. Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009; 60: 443-56.
9. Hirschhorn JN, Gajdos ZK. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annu Rev Med 2011; 62: 11-24.
10. Roden DM, Johnson JA, Kimmel SE, et al. Cardiovascular pharmacogenomics. Circ Res 2011; 109: 807-20.
11. Talameh JA, Lanfear DE. Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep 2012; 9: 23-32.
12. Cappola TP, Dorn GW, 2nd. Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet 2011; 4701-9.
13. Dorn GW, 2nd. The genomic architecture of sporadic heart failure. Circ Res 2011; 108: 1270-83.
14. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9: 1300-5.
15. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103: 11288-93.
16. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009; 54: 432-44.
17. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003; 5: 463-8.
18. Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to betablocker therapy in heart failure. Pharmacogenet Genomics 2007; 17: 277-82.
19. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2Cadrenergic receptor polymorphism alters the norepinephrinelowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3: 21-8.
20. Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-9.
21. Turki J, Lorenz JN, Green SA, et al. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 10483-8.
22. Brodde OE, Buscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103: 1048-50.
23. Wang WC, Mihlbachler KA, Bleecker ER, et al. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics 2008; 18: 729-32.
24. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14: 510-7.
25. Lobmeyer MT, Wang L, Zineh I, et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics 2001; 21: 42-9.
26. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
27. Huang W, Xie C, Zhou H, et al. Association of the angiotensinconverting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail 2004; 6: 23-7.
28. Palmer BR, Pilbrow AP, Yandle TG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 2003; 41: 729-36.
29. Bai Y, Wang L, Hu S, Wei Y. Association of angiotensinconverting enzyme I/D polymorphism with heart failure: a metaanalysis. Mol Cell Biochem 2012; 361: 297-304.
30. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-8.
31. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-8.
32. Andersson B, Sylven C. The DD genotype of the angiotensinconverting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28: 162-7.
33. McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2019-26.
34. Wu CK, Luo JL, Tsai CT, et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 2010; 10: 46-53.
35. Cappola TP, Li M, He J, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet 2010; 3: 147-54.
36. Smith NL, Felix JF, Morrison AC, et al. Association of genomewide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010; 3: 256-66.
37. Callis TE, Jensen BC, Weck KE, Willis MS. Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn 2010; 10: 329-51.
38. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 2013; 123: 19-26.
39. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 366: 619-28.
40. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2011; 57: 1641-9.
41. Van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012; 59: 493-500.
42. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail 2009; 15: 83-97.
43. Lakdawala NK, Funke BH, Baxter S, et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail 2012; 18: 296-303.
44. Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009; 2: 253-61.
45. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009; 302: 2471-6.
46. National Society of Genetic Counselors' Definition Task F, Resta R, Biesecker BB, et al. A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report. J Genet Couns 2006; 15: 77-83.
47. Teekakirikul P, Kelly MA, Rehm HL, et al. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn 2013; 15: 158-70.
48. Patterson C. A good idea: a physician's perspective on genetic counseling for hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009; 2: 508-9.
49. Velagaleti RS, O'Donnell CJ. Genomics of heart failure. Heart Fail Clin 2010; 6: 115-24.